Enquirer Consulting Group

Reachable Buyer Map

Prepared for Tathagata Dutta, Jodas Expoim · August 2026
Here is the map. It covers Europe, which is where your EU GMP and PIC/S approvals already stand, and it sorts the market by who signs for an injectable rather than by who administers it. In this market first contact usually happens through an importer or an agent who already holds the relationship, which is why the buyer above them is rarely met directly. Jodas is headquartered in Hyderabad, so every count below is European, not global.
National tender and central procurement bodies
The largest single decision in the region by volume, and the one furthest from any distributor conversation. Most countries buy centrally or through a small number of regional purchasers, a few leave it with the hospital, and the rules differ enough that the segment is worked country by country rather than as one list.
Who signs: the head of pharmaceutical procurement, the tender committee chair, the category manager for injectables, and the national medicines agency contact on the qualification step.
Roughly 30 countries
across the European Union, the wider European Economic Area and the United Kingdom
Hospitals and hospital groups
The recurring buyer, and the one that decides what is actually stocked once a national listing exists. Cephalosporins, critical care and contrast media are bought here in real volume and reordered without ceremony. The count below is hospitals as sites; the number of owning groups and networks is far smaller.
Who signs: the chief pharmacist, the head of pharmacy purchasing, the oncology pharmacy lead, and the medical director.
13,000 to 15,000
hospitals across the region; owning groups are far fewer
Marketing authorization holders and in licensing partners
The route that does not wait for you to hold every national approval yourself. A European company with a portfolio gap takes the product, carries the filing and sells it under its own name. Slow to start and durable once running. Stated plainly: there is no single public register of who is looking for what, so this segment is built one company and one molecule at a time.
Who signs: the head of business development, the portfolio director, the in licensing manager, and the regulatory affairs director.
No single register
identified by product and by country, one at a time
Wholesalers, importers and distributors
The layer every exporter already knows, listed here because the map would be dishonest without it. Licensed nationally rather than centrally, so there is no one European list to buy. The useful point is that this layer reaches the shelf and does not reach the tender, and a business that only talks to it never meets the two rows above.
Who signs: the managing director, the head of procurement, and the category lead for hospital products.
Several hundred
licensed wholesalers across the region, held country by country
Contract manufacturing and capacity buyers
A different sale from the same plant. Seven manufacturing lines across the general injectables, cephalosporin and oncology blocks, as your own site describes them, is capacity that European companies buy directly when their own supply fails an inspection or their volumes outgrow a site. The trigger is somebody else's problem, and it is usually public before it is solved.
Who signs: the head of external manufacturing, the supply chain director, the chief operating officer, and the quality lead on the audit.
No public register
reached by name, usually on the back of a published supply event

Where the openings are

1
An importer relationship reaches the shelf. It does not reach the person who writes the tender. Those are two different buyers with two different calendars. In this market an agent typically carries several manufacturers at once, so the tender side of that pair rarely gets a direct conversation from anyone.
2
This is bought at a moment, not on a cycle. A published shortage notice, a tender window opening, a competitor failing an inspection, a hospital group consolidating its formulary. Those moments are published across the region, and watching all of them at once is a mechanical job that a distributor network cannot do for you.
3
The largest recurring group is the hospital pharmacy. Roughly 13,000 to 15,000 hospitals across the region, reached one chief pharmacist at a time, and almost never reached at all by a manufacturer that sells through agents.
4
This is a distribution gap, not a credibility one. Making the product to EU GMP standard is your discipline and you do not need help with it. The machinery that puts a case in front of several thousand named European buyers on a schedule, in their language, and tracks what comes back is a build, and most firms in this category never make it. That is the part we build, and we hand it over when it works.
Built from published European health statistics and from public regulatory and trade registers, current to the most recent published year. Counts are banded deliberately. Hospitals are counted as sites rather than as owners, and one group can run many of them, so the rows read as scale rather than as a target list and are not meant to be added together. Where no public register exists, the row says so rather than guessing. It describes the market rather than your business, and there is nothing to buy at the end of it.
ENQUIRER CONSULTING GROUP
enquirerconsulting.com